Reclipsen Kit
Product Images NDC 0093-3304

7 FDA label images from Teva Pharmaceuticals Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Reclipsen (NDC 0093-3304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula 1 (Image 1)

Structural Formula 1 (Image 1)
Chemical structure diagram of the active ingredient Ethinyl Estradiol from the prescription drug Reclipsen 28 Day (Desogestrel and Ethinyl Estradiol). The image displays the molecular structure composed of carbon, hydrogen, and oxygen atoms forming the steroid framework with characteristic hydroxyl and ethynyl functional groups.*
FDA Label Image

Structural Formula 2 (Image 2)

Structural Formula 2 (Image 2)
Chemical structure of Desogestrel and Ethinyl Estradiol, the active ingredients in Reclipsen 28 Day. The image depicts the molecular structure characteristic of steroid hormones, including rings and functional groups.*
FDA Label Image

Table I (Image 3)

Table I (Image 3)
A bar chart showing mortality rate (number of deaths per 100,000 woman-years) categorized by age groups (15-24, 25-34, 35-44, 45 and older). The data compares mortality rates among ever-users (non-smokers and smokers) and controls (non-smokers and smokers), with distinct shading for each group.*
FDA Label Image

Figure 2 (Image 4)

Figure 2 (Image 4)
A forest plot titled 'Risk of Breast Cancer with Combined Oral Contraceptive Use' showing effect estimates (OR/RR) from various women's health studies between 2002 and 2017. The horizontal axis ranges from -1.5 to 2 with individual study results depicted as points with confidence intervals. Studies include NICHD, French E3N, Shangai Women's Health, Nurses' Health, Oxford Family Planning, and Danish Sex Hormone Register. Effect estimates are mostly around 1, with some slightly above, indicating relative risk evaluations.*
FDA Label Image

Blister (Image 5)

Blister (Image 5)
Reclipsen 28 Day oral contraceptive tablet pack with 28 round tablets arranged in 4 rows by 7 columns. The top three rows contain gray tablets, and the bottom row contains white tablets. Days of the week are labeled above each column from Sunday to Saturday. The pack indicates a dosage of 0.15 mg desogestrel and 0.03 mg ethinyl estradiol per tablet. The labeler is Teva Pharmaceuticals USA, Inc. The product is a human prescription drug with NDC 0093-3304 and provided as a 28-day kit.*
FDA Label Image

Image (Image 6)

Image (Image 6)
Reclipsen 28 Day kit containing desogestrel and ethinyl estradiol tablets USP 0.15 mg/0.03 mg. The label shows 6 cyclic tablet dispensers, each with 28 tablets. The packaging includes storage instructions, dosage regimen of 28 days, and is labeled by Teva Pharmaceuticals USA, Inc. with the Rx only symbol and a logo for Shaping Women's Health.*
FDA Label Image

Image (Image 7)

Image (Image 7)
Box label for Reclipsen 28 Day kit containing desogestrel and ethinyl estradiol tablets USP 0.15 mg/0.03 mg. The label states the kit includes 6 cyclic tablet dispensers with 28 tablets each. The labeler is Teva Pharmaceuticals USA, Inc. The packaging features yellow vertical stripes and includes prescribing information disclaimers and barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.